For how we live.
JAMA published paired systematic reviews for the coming respiratory season. Both found vaccines reduced hospitalisation across age groups, with no new safety signals, though protection wanes over time.
Two pragmatic randomised trials and a Medicare nursing home cohort landed in the same week. Together they show real protection against hospitalisation and a durability question nobody has answered.
Three surveillance networks put 2025/26 effectiveness between 22% and 45% against a drifted H3N2 virus. The figure is a comparison between vaccinated and unvaccinated people who all got tested.
Two national studies settle the question the trials could not: in England, cancer rates fell 87% among those vaccinated at 12-13; in Sweden, the risk was cut by nearly two-thirds.
A Buenos Aires surveillance cohort estimates 80.8% effectiveness against RSV hospitalisation in infants under three months — close to what the licensing trial found, in a real programme.